SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells

Oncogene

Volumn 31, Issue 26, 2012, Pages 3148-3163

  Canino, C ^a   Mori, F ^a   Cambria, A ^b   Diamantini, A ^c   Germoni, S ^a   Alessandrini, G ^d   Borsellino, G ^c   Galati, R Z ^a   Battistini, L ^c   Blandino, R ^b   Facciolo, F ^d   Citro, G ^a   Strano, S ^a   Muti, P ^a   Blandino, G ^a   Cioce, M ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b S Vincenzo Hospital   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

chemoresistance; EMT; mesothelioma; SASP

Indexed keywords

ALDEHYDE DEHYDROGENASE; CYTOKINE; PEMETREXED; PROTEIN P53; RAS PROTEIN; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL AGING; CELL EXPANSION; CELL POPULATION; CELL SELECTION; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MITOGENESIS; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PHENOTYPE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ALDEHYDE DEHYDROGENASE; ANIMALS; CELL AGING; CELL COUNT; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CULTURE MEDIA, CONDITIONED; CYTOKINES; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, RAS; GLUTAMATES; GUANINE; HUMANS; MALE; MESODERM; MESOTHELIOMA; MICE; MITOGENS; PHENOTYPE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

MUS;

EID: 84863208596     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.485     Document Type: Article

References (49)

1. Achcar Rde O, Cagle PT, Jagirdar J. (2007). Expression of activated and latent signal transducer and activator of transcription 3 in 303 non-small cell lung carcinomas and 44 malignant mesotheliomas: possible role for chemotherapeutic intervention. Arch Pathol Lab Med 131: 1350-1360. (Pubitemid 47427588)
2. Adhikari AS, Agarwal N, Iwakuma T. (2011). Metastatic potential of tumor-initiating cells in solid tumors. Front Biosci 16: 1927-1938.
3. Albonici L, Doldo E, Palumbo C, Orlandi A, Bei R, Pompeo E et al. (2009). Placenta growth factor is a survival factor for human malignant mesothelioma cells. Int J Immunopathol Pharmacol 22: 389-401.
4. Aroeira LS, Aguilera A, Sanchez-Tomero JA, Bajo MA, del Peso G, Jimenez-Heffernan JA et al. (2007). Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 18: 2004-2013. (Pubitemid 47041064)
5. Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K et al. (2010). PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141: 166-177.
6. Ben-Porath I, Weinberg RA. (2004). When cells get stressed: an integrative view of cellular senescence. J Clin Invest 113: 8-13. (Pubitemid 38541623)
7. Campisi J. (2001). Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol 11: S27-S31.
8. Casarsa C, Bassani N, Ambrogi F, Zabucchi G, Boracchi P, Biganzoli E et al. (2011). Epithelial-to-mesenchymal transition, cell polarity and stemness-associated features in malignant pleural mesothelioma. Cancer Lett 302: 136-143.
9. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B et al. (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 16: 45-55.
10. Cioce M, Gherardi S, Viglietto G, Strano S, Blandino G, Muti P et al. (2010). Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like-and early progenitortargeting drugs. Cell Cycle 9: 2878-2887.
11. Coppe JP, Desprez PY, Krtolica A, Campisi J. (2010). The senescenceassociated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 5: 99-118.
12. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J et al. (2008). Senescence-associated secretory phenotypes reveal cellnonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6: 2853-2868.
13. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. (2007). MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67: 8433-8438. (Pubitemid 47437414)
14. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. (2009). Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 4: 1798-1806.
15. Fujino S, Yokoyama A, Kohno N, Hiwada K. (1996). Interleukin 6 is an autocrine growth factor for normal human pleural mesothelial cells. Am J Respir Cell Mol Biol 14: 508-515. (Pubitemid 126442942)
16. Galffy G, Mohammed KA, Dowling PA, Nasreen N, Ward MJ, Antony VB. (1999). Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res 59: 367-371. (Pubitemid 29048869)
17. Hazarika M, White Jr RM, Booth BP, Wang YC, Ham DY, Liang CY et al. (2005). Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11: 982-992. (Pubitemid 40175745)
18. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134. (Pubitemid 47014436)
19. Hermeking H. (2007). p53 enters the microRNA world. Cancer Cell 12: 414-418. (Pubitemid 350046413)
20. Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ et al. (2010). Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 1203: 7-14.
21. Huang C, Jiang T, Zhu L, Liu J, Cao J, Huang KJ et al. (2011a). STAT3-targeting RNA interference inhibits pancreatic cancer angiogenesis in vitro and in vivo. Int J Oncol 38: 1637-1644.
22. Huang C, Yang G, Jiang T, Zhu G, Li H, Qiu Z. (2011b). The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. Neoplasma 58: 396-405.
23. Kim C, Kim DG, Park SH, Hwang YI, Jang SH, Kim CH et al. (2011). Epithelial to mesenchymal transition of mesothelial cells in tuberculous pleurisy. Yonsei Med J 52: 51-58.
24. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S et al. (2011). Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer.
25. Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J et al. (2011). Epigenetic silencing of microRNA-34b/c lays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 17: 4965-4974.
26. Laberge RM, Awad P, Campisi J, Desprez PY. (2011). Epithelialmesenchymal transition induced by senescent fibroblasts. Cancer Microenviron.
27. Li Q, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y et al. (2007). The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res 13: 5918-5925. (Pubitemid 47583920)
28. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F et al. (2011). Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71: 614-624.
29. Ma I, Allan AL. (2011). The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7: 292-306.
30. Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M et al. (2011). Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 29: 32-45.
31. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K et al. (1992). p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 52: 2610-2615.
32. Mor O, Yaron P, Huszar M, Yellin A, Jakobovitz O, Brok-Simoni F et al. (1997). Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 16: 9-13. (Pubitemid 127497429)
33. Mujoomdar AA, Tilleman TR, Richards WG, Bueno R, Sugarbaker DJ. (2010). Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: Result in a cohort of 203 resection specimens. J Thorac Cardiovasc Surg 140: 352-355.
34. Oka M, Sakaguchi M, Okada T, Nagai H, Ozaki M, Yoshioka T et al. (2010). Signal transducer and activator of transcription 3 upregulates interleukin-8 expression at the level of transcription in human melanoma cells. Exp Dermatol 19: e50-e55.
35. Park JS, Kim YS, Jee YK, Myong NH, Lee KY. (2003). Interleukin-8 production in tuberculous pleurisy: role of mesothelial cells stimulated by cytokine network involving tumour necrosis factoralpha and interleukin-1 beta. Scand J Immunol 57: 463-469. (Pubitemid 36577906)
36. Pompeo E, Albonici L, Doldo E, Orlandi A, Manzari V, Modesti A et al. (2009). Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. Ann Thorac Surg 88: 426-431.
37. Rodier F, Kim SH, Nijjar T, Yaswen P, Campisi J. (2005). Cancer and aging: the importance of telomeres in genome maintenance. Int J Biochem Cell Biol 37: 977-990. (Pubitemid 40311740)
38. Ruco LP, de Laat PA, Matteucci C, Bernasconi S, Sciacca FM, van der Kwast TH et al. (1996). Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma. J Pathol 179: 266-271. (Pubitemid 26266404)
39. Scarpa S, Giuffrida A, Palumbo C, Coletti A, Cerrito MG, Vasaturo F et al. (2002). Retinoic acid inhibits fibronectin and laminin synthesis and cell migration of human pleural mesothelioma in vitro. Oncol Rep 9: 205-209.
40. Schindler C, Levy DE, Decker T. (2007). JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282: 20059-20063. (Pubitemid 47099977)
41. Schramm A, Opitz I, Thies S, Seifert B, Moch H, Weder W et al. (2010). Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. Eur J Cardiothorac Surg 37: 566-572.
42. Sidi R, Pasello G, Opitz I, Soltermann A, Tutic M, Rehrauer H et al. (2011). Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis. Eur J Cancer 47: 326-332.
43. Sivertsen S, Hadar R, Elloul S, Vintman L, Bedrossian C, Reich R et al. (2006). Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer 54: 309-317. (Pubitemid 44740263)
44. Suzuki Y, Sakai K, Ueki J, Xu Q, Nakamura T, Shimada H et al. (2010). Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer 127: 1948-1957.
45. Takeda K, Akira S. (2000). STAT family of transcription factors in cytokine-mediated biological responses. Cytokine Growth Factor Rev 11: 199-207. (Pubitemid 30337459)
46. Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B, Muller KM. (1998). Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124: 291-296. (Pubitemid 28332909)
47. Wang L, Park P, Zhang H, La Marca F, Lin CY. (2011). Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 128: 294-303.
48. Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V et al. (2011). Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA 108: 11590-11595.
49. Young AR, Narita M. (2009). SASP reflects senescence. EMBO Rep 10: 228-230.